- TACRINE HYDROCHLORIDE
-
- $1.10 / 1g
-
2025-06-25
- CAS:1684-40-8
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
- TACRINE HYDROCHLORIDE
-
- $15.00 / 1KG
-
2021-07-02
- CAS:1684-40-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | TACRINE HYDROCHLORIDE Basic information |
| Product Name: | TACRINE HYDROCHLORIDE | | Synonyms: | 1,2,3,4-tetrahydro-9-acridinaminmonohydrochloride;1,2,3,4-tetrahydro-9-aminoacridinehydrochloride;1,2,3,4-tetrahydro-9-amino-acridinmonohydrochloride;9-amino-1,2,3,4-tetrahydro-acridinhydrochloride;tacrine monohydrochloride;1,2,3,4-TETRAHYDRO-9-ACRYDINAMINEHCLMONOHYDRATE;1,2,3,4-TETRAHYDRO-9-ACRIDINAMINEHYDROCHLORIDEMONOHYDRATE;1,2,3,4-Tetrahydro-9-Acridinamine Hydrochloride Dihydrate | | CAS: | 1684-40-8 | | MF: | C13H15ClN2 | | MW: | 234.72 | | EINECS: | 216-867-5 | | Product Categories: | COGNEX;Chemical Amines;Amines;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;Acetylcholine receptor | | Mol File: | 1684-40-8.mol |  |
| | TACRINE HYDROCHLORIDE Chemical Properties |
| Melting point | 280-284 °C(lit.) | | storage temp. | Inert atmosphere,2-8°C | | solubility | Soluble in aqueous buffers | | pka | pKa 9.8 (Uncertain) | | form | Crystalline solid | | color | White to light yellow | | InChI | InChI=1S/C13H14N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1,3,5,7H,2,4,6,8H2,(H2,14,15);1H | | InChIKey | ZUFVXZVXEJHHBN-UHFFFAOYSA-N | | SMILES | C12=CC=CC=C1C(N)=C1CCCCC1=N2.Cl | | CAS DataBase Reference | 1684-40-8(CAS DataBase Reference) | | EPA Substance Registry System | Tacrine hydrochloride (1684-40-8) |
| Hazard Codes | T,Xn | | Risk Statements | 25-36/37/38-20/22 | | Safety Statements | 26-36-45 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | AR9532500 | | HazardClass | 6.1(a) | | PackingGroup | II | | Toxicity | LD50 intravenous in mouse: 5600ug/kg |
| | TACRINE HYDROCHLORIDE Usage And Synthesis |
| Description | Tacrine is the first therapeutic launched specifically for the treatment of Alzheimer's
disease which affects four million people in the US alone. Clinically significant improvement in
cognition has been demonstrated in the patients with Alzheimer's disease. Although the
cause of Alzheimer's disease is not understood, degeneration of cholinergic neurons is
thought to be a primary factor in the development and progression of the disease. Tacrine is a
reversible acetylcholinesterase inhibitor that presumably acts centrally by elevating the
acetylcholine level in the cerebral cortex and by slowing degradation of acetylcholine from
intact cholinergic neurons. While tacrine improves the symptoms of Alzheimer's disease, the
underlining cause of the dementing process is not altered. It has also been suggested that the
beneficial effects of tacrine may be due to its multiple effects on several neurotransmitter
systems. | | Description | Tacrine is a derivative of aminoacridine that functions as an inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (IC50s = 31 and 26.5 nM, respectively). Tacrine also inhibits the uptake of serotonin and norepinephrine in rat cerebral cortex and decreases depolarization-induced calcium influx through L-type calcium channels in SN56 neuronal cells. Formulations containing tacrine have been used clinically in the treatment of Alzheimer’s disease. | | Chemical Properties | Pale Yellow Solid | | Originator | NIH (U.S.A.) | | Uses | anticholinesterase, cognitive adjuvant, K channel blocker | | Uses | A potent centrally acting anticholinesterase, for therapy of memory deficits in patients with Alzheimers disease. THA also selectively blocks potassium channels in the central nervous system, which results in an increased release of acetylcholi | | Uses | A potent centrally acting anticholinesterase for therapy of memory deficits in patients with Alzheimer's disease. THA also selectively blocks potassium channels in the central nervous system, which results in an increased release of acetylcholine and a prolongation of the action potential of the presynaptic cholinergic neurons. | | Brand name | Cognex (Sciele). | | General Description | Tacrine hydrochloride,1,2,3,4-tetrahydro-9-aminoacridine hydrochloride (THA,Cognex), is a reversible cholinesterase inhibitor that hasbeen used in the treatment of Alzheimer disease for severalyears. The drug has been used to increase the levels of AChin these patients on the basis of observations from autopsiesthat concentrations of ChAT and AChE are markedly reducedin the brain, whereas the number of muscarinic receptorsis almost normal. The use of the drug is not withoutcontroversy, as conflicting results on efficacy have been reported.The drug has been used in mild-to-moderateAlzheimer dementia. | | General Description | Yellow needles (from concentrated hydrochloric acid); white powder. pH of 1.5% solution: 4.5-6. Bitter taste. | | Air & Water Reactions | Water soluble. | | Reactivity Profile | TACRINE HYDROCHLORIDE is incompatible with strong oxidizing agents, acid chlorides and acid anhydrides . Neutralize bases in slightly exothermic reactions. | | Fire Hazard | Flash point data for TACRINE HYDROCHLORIDE are not available; however, TACRINE HYDROCHLORIDE is probably combustible. | | Biological Activity | Potent cholinesterase inhibitor, a cognition enhancer in vivo . | | Metabolism | Tacrine is
extensively metabolized by CYP450 to at least three metabolites. The major metabolite, 1-hydroxy-tacrine, is active. Its elimination half-life is
between 1.5 and 4 hours, with metabolites being are excreted via the urine. |
| | TACRINE HYDROCHLORIDE Preparation Products And Raw materials |
|